

CITATION REPORT

List of articles citing

HER2 directed therapy for gastric/esophageal cancers

DOI: 10.1007/s11864-014-0292-6

Current Treatment Options in Oncology, 2014, 15, 395-404.

Source: <https://exaly.com/paper-pdf/59500356/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
19	Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized Medicine. <i>Advances in Clinical Chemistry</i> , 2015 , 70, 95-130	5.8	10
18	Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. <i>Journal of Gastroenterology</i> , 2015 , 50, 955-61	6.9	9
17	Targeted therapy in gastric cancer. <i>Apmis</i> , 2015 , 123, 365-72	3.4	38
16	The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 750-762	2.8	35
15	ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. <i>Oncotarget</i> , 2016 , 7, 10243-54	3.3	24
14	Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. <i>Oncology Letters</i> , 2016 , 11, 1645-1650	2.6	16
13	Clinical impact of tumour biology in the management of gastroesophageal cancer. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 348-60	19.4	100
12	SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients. <i>Oncology Reports</i> , 2017 , 37, 3433-3440	3.5	4
11	The mechanisms of radioresistance in esophageal squamous cell carcinoma and current strategies in radiosensitivity. <i>Journal of Thoracic Disease</i> , 2017 , 9, 849-859	2.6	37
10	Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells using oxaliplatin-au-fe3o4-herceptin nanoparticles. <i>Oncology Letters</i> , 2018 , 15, 8079-8087	2.6	15
9	Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
8	Long Noncoding RNAs: New Regulators of Resistance to Systemic Therapies for Gastric Cancer. <i>BioMed Research International</i> , 2021 , 2021, 8853269	3	5
7	MEX3A is upregulated in esophageal squamous cell carcinoma (ESCC) and promotes development and progression of ESCC through targeting CDK6. <i>Aging</i> , 2020 , 12, 21091-21113	5.6	6
6	Role of intravoxel incoherent motion MR imaging in preoperative assessing HER2 status of gastric cancers. <i>Oncotarget</i> , 2017 , 8, 49293-49302	3.3	8
5	Targeted therapy for advanced gastric cancer: A review of current status and future prospects. <i>World Journal of Gastrointestinal Oncology</i> , 2015 , 7, 401-10	3.4	18
4	HER-2/neu Overexpression in Esophageal Squamous Cell Carcinoma (ESCC) and Its Correlation with Patient's Clinicopathological Features. <i>Iranian Journal of Cancer Prevention</i> , 2016 , In Press,		
3	Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. 2018 , 191-224		

- 2 A Bispecific Antibody Targeting HER2 and PD-L1 Inhibits Tumor Growth with Superior Efficacy. *Journal of Biological Chemistry*, **2021**, 101420 5·4 4
- 1 HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities.. *Clinical and Translational Medicine*, **2022**, 12, e791 5·7